We are happy to announce that the enrolment of 40 participants within CHOICES has been successfully completed. CHOICES is the clinical trial of the HIT-CF project, and assesses the efficacy and safety of a new triple modulator therapy in people with CF with ultra-rare variants that were pre-selected using the innovative organoid test. You can read all about this important milestone in the press release. The first results of the trial are expected mid-2025 and we will share them as soon as possible.